While sequencing technology is getting better and faster, it still isn't quite ready to be put to frequent use in the oncology ward, write the Wellcome Trust Center for Human Genetics' Danny Ulahannan and colleagues in a review in the British Journal of Cancer.

In the research setting, they note, there are still challenges in calling low-frequency variants that appear in cancer genomes as well as issues in identifying structural and copy-number variants.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.